Navigation Links
Two-Year Follow-Up Data Show Outstanding Clinical Outcomes and Safety for OrbusNeich's Genous™ Stent in Patients at High Risk for Restenosis
Date:8/16/2011

HONG KONG, Aug. 16, 2011 /PRNewswire/ -- OrbusNeich today announced that the that the company's Genous Stent showed no significant difference in the rate of target vessel failure (TVF) at two years compared to the Taxus Liberte™ paclitaxel-eluting stent in patients with de novo coronary artery lesions carrying a high risk for restenosis.  The two-year follow-up data from the prospective, randomized TRIAS pilot study were published in Catheterization and Cardiovascular Interventions.

No cases of stent thrombosis (ST) were observed in patients treated with the Genous Stent at two years, compared to five cases of ST observed in four patients treated with Taxus. The cumulative rate of cardiac death or myocardial infarction (MI) was 4.1 percent in the Genous group compared to 6.3 percent in the Taxus group.

"It is noteworthy that we did not see any stent thrombosis in patients with complex lesions treated with the Genous Stent," said Marcel Beijk, M.D., of the Academic Medical Center, Amsterdam, and lead author of the paper. "We also saw that the Genous Stent tended to have fewer episodes of target lesion revascularization between one and two years."

The single-center study investigated 193 patients of which 98 received a Genous Stent and 95 received a Taxus stent. Dual antiplatelet therapy was prescribed for at least one month after Genous Stent implantation and for at least six months after Taxus stent implantation.

"For patients with a high risk of restenosis who cannot tolerate the long-term dual antiplatelet therapy normally associated with DES, it is clear that the Genous Stent is an excellent alternative," added Prof. Robbert de Winter, M.D., Ph.D., also of the Academic Medical Center, Amsterdam, and an author of the paper.

The study's primary endpoint was TVF and secondary endpoints included non-cardiac death, target lesion revascul
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices
2. Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) EXPRESS(R) Stents and Bypass Surgery
3. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
4. Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162
5. Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
6. Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
7. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
8. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
9. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
10. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
11. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014  Diplomat, the nation,s largest independent specialty ... winners in the 2014 Innovations in Specialty Pharmacy ... results of the competition were announced in the ... Diplomat was honored as a Top ... program. Through Diplomat University, the company has implemented ...
(Date:8/22/2014)... 22, 2014  Dr. Mark Rasak , MD ... Lifetime Achievement Award in the field of Medicine as ... Clinical Associates. Dr. Rasak has over 15 ... aspects of the business; overseeing the daily operations; interventional ... intervention. In addition, he is an honored Fellow of ...
(Date:8/22/2014)... , Aug. 22, 2014 Research ... "Global and Chinese Particulate Respirators Industry Report 2014" ... Global and Chinese Particulate Respirators Industry Report 2014 is ... of the global particulate respirators industry with a focus ... basic overview of the industry including definitions, classifications, applications ...
Breaking Medicine Technology:Diplomat honored as a Top Innovator by Specialty Pharmacy News 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Global and Chinese Particulate Respirators Industry Report 2014 2
... FALLS CHURCH, Va., May 19, 2011 MinuteClinic, the ... CVS ), and Inova Health System, a leading ... million patients a year, have entered into a clinical ... care services they provide in communities throughout Arlington, Fairfax, ...
... Ampio Pharmaceuticals, Inc. (Nasdaq Capital Market: AMPE) ("Ampio" ... for previously approved drugs and new molecular entities ("NMEs"), ... on the NASDAQ Capital Market under the ticker symbol ... Wingerter, the Company,s CEO, said, "We are extremely excited ...
Cached Medicine Technology:MinuteClinic Forms Strategic Affiliation With Inova Health System in Northern Virginia 2MinuteClinic Forms Strategic Affiliation With Inova Health System in Northern Virginia 3MinuteClinic Forms Strategic Affiliation With Inova Health System in Northern Virginia 4Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market 2
(Date:8/22/2014)... 2014 Mi40x , the latest guide ... show people how they can use a simple 4-minute trick ... matter of weeks has caught the attention of Shane Michaels, ... of the most well-known bodybuilders in the industry, and if ... today, that in itself is a testament to how effective ...
(Date:8/22/2014)... Paying tuition and other related educational expenses ... for four nurse educators pursuing advanced degrees, thanks to ... Foundation for Nursing Education . This year’s recipients – ... than in 2013, thanks to these named NLN Foundation ... Marcil Endowment Funds, both donated by Kathy Mershon; the ...
(Date:8/22/2014)... 2014 Mueller Sports Medicine is excited ... exciting new product that provides non-drug instant relief for ... while you heal. The package includes 7 days of ... technology – it is not kinesiology tape. It’s made ... System for Plantar Fasciitis is a breakthrough in ...
(Date:8/22/2014)... West Orange, NJ. August 22, 2014. A ... shows that persons with multiple sclerosis (MS) may ... cognitive rehabilitation. The study was epublished ahead of ... (Yael Goverover, Helen Genova, Hali Griswold, Nancy D. ... awareness in persons with multiple sclerosis doi: 10.3233/NRE-141113). ...
(Date:8/22/2014)... Menstrual leaks risk stains and embarrassment, ... decided that there needed to be a better way ... producible in design variations, the Safety Net optimizes protection ... avoids embarrassment and promotes peace of mind. The pad ... The original design was submitted to the Fort Lauderdale ...
Breaking Medicine News(10 mins):Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... have developed a Vitamin D pill that could give a ... of prostrate cancer when given along with chemotherapy drugs. ... lived for an average of an extra nine months longer ... edition of BBC News. ,The pill delivers ...
... transplantation—including the psychological and ethical aspects// of the controversial ... of England now endorses moving cautiously forward in performing ... the Jan. 27 issue of Transplantation. ,In ... that facial transplantation should not be attempted until further ...
... new study by researchers at the Harvard School of ... United States //has resulted in a net savings of ... benefits associated with avoided fear and suffering. This first ... vaccination appears as part of a special issue on ...
... gamblers in Britain. A study reveals// that Englishmen prefer to ... fruits. ,On an average, ?800 per year ... Online gambling has also increased the number of gamblers over ... (BMA) has expressed its apprehensions and fears about teenagers getting ...
... pressure in the arteries. High blood pressure (hypertension) //is often ... for years without knowing it. ,A person is ... is around 120/80. Canadians regard blood pressure with systolic reading ... and 89 as high-normal blood pressure. ,Approx. 2.5 ...
... Hospitals, one of the largest eye care hospital networks in ... seven more in the offing. ,The Chennai facility ... prominent ophthalmic surgeon and managing director of Prems' Eye Clinic. ... ,The Vasan Eye Care Group has earmarked a Rs.450 million ...
Cached Medicine News:Health News:Royal College Issues Revised Guidelines for Face Transplantation 2Health News:Royal College Issues Revised Guidelines for Face Transplantation 3Health News:Billions of Dollars Saved in U.S. By Polio Vaccination 2Health News:Slightly High Blood Pressure is Also Hazardous 2
... combination of the Aliquoting System RSD 800A ... ACM-8). This turns out in an efficient ... laboratory. The System automates all important front-end ... via cap identification, sample quality control, decapping, ...
... The Aliquoting System RSD 800A is an ... and archiving (additional tube type identification via ... to process various sample tubes in a ... sorting areas are customized and offer high ...
... Sorting System RS 800 can sort different ... manual sorting are not necessary anymore and ... in a very timesaving and economical way ... Optionally a Tube Type Identification via Cap ...
... MGB Alert Detection Reagents provide molecular labs ... based assays. By using our MGB technology, ... Nanogen is now able to provide molecular ... acid sequences of specific organisms or genetic ...
Medicine Products: